BioNTech is a global next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Founded in 2008 by scientists and physicians Prof. Ugur Sahin, Prof. Özlem Türeci, and Prof. Christoph Huber, we're dedicated to translating scientific discoveries into life-saving treatments. Our diversified portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs), and innovative CAR-T cell therapies designed to address the full continuum of cancer - from early-stage disease with high recurrence risk to advanced and metastatic cancers.
We believe in the immune system as the fundamental driver for therapeutic success. With deep capabilities in immunology, mRNA research and development, in-house manufacturing, deep genomics, and artificial intelligence, we've developed the first approved mRNA medicinal product for COVID-19 in partnership with Pfizer. Now we're applying that same scientific rigor to our original focus: oncology. We operate as a fully-integrated biotechnology company with global sites spanning discovery, development, and commercialization, all driven by our vision to translate science into survival.
